Evidence map›Paper›PMID 37205513›Full record

ArticlebioRxiv : the preprint server for biology2024

Key role of down-regulated in adenoma (

Jessica B Sarthi, Annie M Trumbull, Shayda M Abazari, Vincent van Unen, Joshua E Chan, Yanfen Jiang, Jesse Gammons, Marc O Anderson, Onur Cil, Calvin J Kuo and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jessica B SarthiDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA.
Annie M TrumbullDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA.
Shayda M AbazariDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA.
Vincent van UnenDepartment of Medicine, Division of Hematology, Stanford University, Palo Alto, CA, USA.
Joshua E ChanDepartment of Medicine, Division of Hematology, Stanford University, Palo Alto, CA, USA.
Yanfen JiangDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA.
Jesse GammonsDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA.
Marc O AndersonDepartment of Chemistry and Biochemistry, San Francisco State University, San Francisco, CA, USA.
Onur CilDepartment of Pediatrics, University of California San Francisco, San Francisco, CA, USA.
Calvin J KuoDepartment of Medicine, Division of Hematology, Stanford University, Palo Alto, CA, USA.
Zachary M SellersDepartment of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Stanford University, Palo Alto, CA, USA.ORCID 0000-0001-5352-7760
Stanford University · USKessler Institute for Rehabilitation · USSan Francisco State University · USUniversity of California, San Francisco · US

Funding

SynthesisP30DK072517 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VERKMAN, ALAN S · 2005 to 2022
$18.1M
Regulation of actively proliferating and quiescent intestinal stem cellsU01DK085527 · NIDDK · STANFORD UNIVERSITY · PI KUO, CALVIN J · 2009 to 2023
$6.9M
Structure-based Bioengineering of Wnt Surrogates for Intestinal Stem Cell Biology and TherapyR01DK115728 · NIDDK · STANFORD UNIVERSITY · PI GARCIA, KENAN CHRISTOPHER, KUO, CALVIN J · 2018 to 2022
$3.9M
SLC26A3 (DRA) Inhibitors for Treatment of Hyperoxaluria and NephrolithiasisR01DK126070 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CIL, ONUR · 2020 to 2024
$1.6M
CFTR-Independent Bicarbonate Secretion is a Novel CF Therapeutic TargetK08DK124684 · NIDDK · STANFORD UNIVERSITY · PI SELLERS, ZACHARY MICHAEL · 2020 to 2024
$678k
NIDDK NIH HHS K08 DK124684NIDDK NIH HHS P30 DK072517NIDDK NIH HHS R01 DK115728NIDDK NIH HHS R01 DK126070NIDDK NIH HHS U01 DK085527
6 · The paper itself

Abstract

Duodenal bicarbonate secretion is critical to epithelial protection, nutrient digestion/absorption and is impaired in cystic fibrosis (CF). We examined if linaclotide, typically used to treat constipation, may also stimulate duodenal bicarbonate secretion. Bicarbonate secretion was measured in vivo and in vitro using mouse and human duodenum (biopsies and enteroids). Ion transporter localization was identified with confocal microscopy and de novo analysis of human duodenal single cell RNA sequencing (sc-RNAseq) datasets was performed. Linaclotide increased bicarbonate secretion in mouse and human duodenum in the absence of CFTR expression (

Identifiers

PMID37205513
PMCPMC10187319
OpenAlexW4375868209

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.